Search: onr:"swepub:oai:gup.ub.gu.se/327280" >
Safety and effectiv...
Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015-2022): 2022 interim analysis
-
Mercuri, E. (author)
-
Osorio, A. N. (author)
-
Muntoni, F. (author)
-
show more...
-
Buccella, F. (author)
-
Desguerre, I. (author)
-
Kirschner, J. (author)
-
- Tulinius, Mar, 1953 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics
-
de Resende, M. B. D. (author)
-
Morgenroth, L. P. (author)
-
Gordish-Dressman, H. (author)
-
Johnson, S. (author)
-
Kristensen, A. (author)
-
Werner, C. (author)
-
Trifillis, P. (author)
-
Henricson, E. K. (author)
-
McDonald, C. M. (author)
-
Stride Investigator, Stride Investigator (author)
-
Cinrg Dnhs Investigator, Cinrg Dnhs Investigator (author)
-
show less...
-
(creator_code:org_t)
- 2023
- 2023
- English.
-
In: Journal of Neurology. - 0340-5354. ; 270, s. 3896-3913
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- ObjectiveStrategic Targeting of Registries and International Database of Excellence (STRIDE) is an ongoing, international, multicenter registry of real-world ataluren use in individuals with nonsense mutation Duchenne muscular dystrophy (nmDMD) in clinical practice. This updated interim report (data cut-off: January 31, 2022), describes STRIDE patient characteristics and ataluren safety data, as well as the effectiveness of ataluren plus standard of care (SoC) in STRIDE versus SoC alone in the Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS).MethodsPatients are followed up from enrollment for at least 5 years or until study withdrawal. Propensity score matching was performed to identify STRIDE and CINRG DNHS patients who were comparable in established predictors of disease progression.ResultsAs of January 31, 2022, 307 patients were enrolled from 14 countries. Mean (standard deviation [SD]) ages at first symptoms and at genetic diagnosis were 2.9 (1.7) years and 4.5 (3.7) years, respectively. Mean (SD) duration of ataluren exposure was 1671 (56.8) days. Ataluren had a favorable safety profile; most treatment-emergent adverse events were mild or moderate and unrelated to ataluren. Kaplan-Meier analyses demonstrated that ataluren plus SoC significantly delayed age at loss of ambulation by 4 years (p < 0.0001) and age at decline to %-predicted forced vital capacity of < 60% and < 50% by 1.8 years (p = 0.0021) and 2.3 years (p = 0.0207), respectively, compared with SoC alone.ConclusionLong-term, real-world treatment with ataluren plus SoC delays several disease progression milestones in individuals with nmDMD. NCT02369731; registration date: February 24, 2015.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Keyword
- Ataluren
- Effectiveness
- Nonsense mutation Duchenne muscular dystrophy
- Safety
- STRIDE Registry
- muscular-dystrophy
- multicenter
- diagnosis
- Neurosciences & Neurology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Mercuri, E.
-
Osorio, A. N.
-
Muntoni, F.
-
Buccella, F.
-
Desguerre, I.
-
Kirschner, J.
-
show more...
-
Tulinius, Mar, 1 ...
-
de Resende, M. B ...
-
Morgenroth, L. P ...
-
Gordish-Dressman ...
-
Johnson, S.
-
Kristensen, A.
-
Werner, C.
-
Trifillis, P.
-
Henricson, E. K.
-
McDonald, C. M.
-
Stride Investiga ...
-
Cinrg Dnhs Inves ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Neurosciences
- Articles in the publication
-
Journal of Neuro ...
- By the university
-
University of Gothenburg